Thyroid Disorders

Our April 2025 month in review highlights significant advancements in endocrinology, including innovative therapies and FDA approvals that enhance diabetes management.

Chronic hypoparathyroidism requires holistic management addressing more than just calcium normalization to achieve optimal patient outcomes.

Palopegteriparatide’s approval was based on positive data from the global Phase 2 PaTH Forward and Phase 3 PaTHway trials.

Our endocrinology month in review for May 2024 highlights pipeline news in endocrinology and spotlights our coverage of the landmark FLOW trial from ERA 2024.

The FDA has extended the review period for palopegteriparatide in treatment of hyperparathyroidism in adult patients by 3 months to August 14, 2024.

A study suggests that opting for thyroid surgery or radioactive iodine therapy could be better for reducing long-term cardiovascular risk in hyperthyroidism patients compared to medication alone.

Our endocrinology month in review spotlights our most popular content from December 2023. Our list of the most popular content from the past month includes the ADA Standards of Care—2024, label updates, a feature from our This Year in Medicine series, and more!

This endocrine case report from Brady Pregerson, MD, features a woman in her early 50s with a history of type 2 diabetes and hypothyroidism presenting with 5 days of epigastric pain. Can you determine the correct diagnosis?

Thyroid dysfunction was greater among patients with more severe CKD coupled with a high urine protein level.

Announced on December 04, 2023, the approved label changes allow for administration regardless of timing of proton pump administration and for administration 15 minutes before breakfast.

This endocrine case report from Brady Pregerson, MD, features a patients in his mid-70s with a history of hypothyroidism presenting with weeks of nausea, vomiting, and diarrhea without blood but with a 30-pound weight loss. Can you determine the most likely diagnosis?

Data from the open-label extension portion of the phase 3 PaTHway trial detail the long-term effects of TransCon PTH use among people with chronic hypoparathyroidism.

Announced on May 1, the CRL from the FDA expressed concerns related to manufacturing control strategy, but did not express concern related to clinical data submitted as part of the NDA package for TransCon PTH.

Unadjusted rates of hypoparathyroidism were higher in patients who underwent total thyroidectomy and parathyroidectomy at both 30 days and 6 months.

Those with ≥67% of albumin-corrected serum calcium measurements outside of the study-defined limits had 1.9-fold higher odds of experiencing a cardiovascular event compared with patients with <33% of calcium measurements outside the range.

Leveraging data from more than 40,000 Veterans with primary hyperparathyroidism, a new NIA-funded study details the impact of parathyroidectomy on long-term kidney function among these patients.

According to a recent study, nearly 1 in 4 patients with either hypothyroidism or subclinical hypothyroidism suffer from a vitamin B12 deficiency.

This week, the FDA announced that 27 lots of levothyroxine sodium oral solution, used for hypothyroidism, were being recalled due to potentially being subpotent.